Mounjaro vs Wegovy in Canada: Key Differences
Quick answer: Mounjaro and Wegovy are different prescription medications with different active ingredients and Canadian indications. Mounjaro contains tirzepatide, and its current Canadian product monograph centres on glycemic control for type 2 diabetes in adults and certain patients aged 10 to under 18. Wegovy contains semaglutide, and its current Canadian product monograph includes chronic weight management for eligible adults and adolescents aged 12 to under 18, along with additional indications for certain adults.
They are not interchangeable, and they should not be used together. A licensed healthcare provider must review a person’s diagnosis, health history, other prescriptions and individual risks before deciding whether either treatment is appropriate.
Important: This guide is for education only and does not replace medical advice. Product labels, availability and insurance rules can change. Information below reflects Canadian product monographs available in August 2026.
Mounjaro vs Wegovy at a Glance
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Current Canadian indication, summarized | Glycemic control for adults and certain patients aged 10 to under 18 with type 2 diabetes | Chronic weight management for eligible adults and adolescents aged 12 to under 18 |
| Additional Canadian indications | No chronic weight-management indication is listed in the current Mounjaro monograph | Includes reducing the risk of non-fatal myocardial infarction in certain adults and a conditional indication for certain adults with non-cirrhotic MASH |
| Prescription required | Yes | Yes |
| Can they be used together? | No. Their product monographs advise against combining them or using them with another GLP-1 receptor agonist. | |
| Coverage and availability | Depend on indication, province, insurer, pharmacy and supply | Depend on indication, province, insurer, pharmacy and supply |
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide. Tirzepatide acts on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
The current Canadian Mounjaro product monograph includes use, along with diet and physical activity, to improve glycemic control in adults with type 2 diabetes. It also includes certain patients aged 10 to under 18 with type 2 diabetes when used with specific diabetes treatments.
Mounjaro has its own contraindications, warnings and monitoring needs. It is not a substitute for insulin and is not indicated for type 1 diabetes or diabetic ketoacidosis.
What Is Wegovy?
Wegovy is the brand name for semaglutide. Semaglutide acts on the GLP-1 receptor.
The current Canadian Wegovy product monograph includes chronic weight management for eligible adults and certain adolescents aged 12 to under 18. Eligibility is based on clinical criteria described in the product monograph and must be assessed by a licensed healthcare provider.
The monograph also includes an indication to reduce the risk of non-fatal myocardial infarction in certain adults with established cardiovascular disease. It has a conditional indication for certain adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, and moderate to advanced liver fibrosis. A conditional authorization means further evidence is required to confirm the clinical benefit.
What Are the Main Differences?
1. Their Canadian-approved uses are different
This is the most important difference. Mounjaro’s current Canadian label centres on type 2 diabetes. Wegovy’s label includes chronic weight management and other specific indications.
Sharing some biological pathways does not make the two brand-name products interchangeable. Brand names, indications and product monographs matter when interpreting online comparisons.
2. They contain different active ingredients
Mounjaro contains tirzepatide. Wegovy contains semaglutide. Tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide acts on the GLP-1 receptor.
This difference may affect how a provider reviews treatment options, but it does not make one product appropriate for every patient.
3. Their age criteria are not the same
The Mounjaro monograph includes certain patients aged 10 to under 18 with type 2 diabetes. The Wegovy monograph includes certain adolescents aged 12 to under 18 for chronic weight management.
The criteria are not interchangeable. A provider must consider the patient’s age, diagnosis and the full requirements in the relevant monograph.
4. Wegovy has additional Canadian indications
Beyond chronic weight management, Wegovy’s current monograph includes specific cardiovascular and liver-related indications for certain adults. Mounjaro’s current monograph does not list those same indications.
An indication on one label should not be assumed to apply to the other product simply because both are part of the broader incretin treatment category.
5. Insurance coverage may follow the approved indication
Private insurance and public coverage rules may differ based on the prescribed product, diagnosis, eligibility criteria and plan. Coverage for one product does not guarantee coverage for the other.
Is Mounjaro Approved for Chronic Weight Management in Canada?
The current Canadian Mounjaro product monograph does not list a chronic weight-management indication. Its listed indication centres on glycemic control in type 2 diabetes.
Tirzepatide is also the active ingredient in Zepbound, which is a separate brand-name product with its own Canadian product monograph and indications. Mounjaro and Zepbound should not be treated as the same brand or label, even though they contain the same active ingredient.
What Does Head-to-Head Research Tell Us?
The SURMOUNT-5 clinical trial compared tirzepatide with semaglutide in adults with obesity who did not have type 2 diabetes. The study reported a difference between the groups in average changes in body weight and waist circumference under its specific research conditions.
However, this was not a direct comparison of the Canadian Mounjaro diabetes label with the Canadian Wegovy label. It studied active ingredients under obesity-treatment protocols. The findings should not be used on their own to decide which brand or treatment is appropriate for an individual patient.
When reading a comparison online, check whether it is discussing:
- A brand-name product or an active ingredient
- Type 2 diabetes or chronic weight management
- A Canadian-approved indication or a study outcome
- A direct clinical trial or an indirect comparison
- Patients whose health profiles match the person asking the question
What Do Mounjaro and Wegovy Have in Common?
Although their labels differ, they share several important features:
- Both require a prescription in Canada.
- Both require an individual clinical assessment.
- Both have thyroid tumour warnings and related contraindications.
- Both may cause gastrointestinal side effects.
- Both have warnings related to pancreatitis, gallbladder problems and dehydration.
- Both can increase the risk of low blood sugar when used with certain diabetes treatments.
- Neither should be combined with another GLP-1 receptor agonist.
Side Effects and Safety Considerations
Commonly reported effects for both products are mainly gastrointestinal. These may include nausea, diarrhea, vomiting, constipation, abdominal discomfort or reduced appetite. The exact side-effect profile and frequency are not identical.
More serious concerns can include pancreatitis, gallbladder disease, severe allergic reactions, kidney injury related to dehydration and severe gastrointestinal symptoms. Both monographs also include warnings about thyroid C-cell tumours based on animal studies. It is not known whether these tumours occur in humans because of either treatment.
A healthcare provider should review factors such as:
- A personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Previous pancreatitis or gallbladder disease
- Kidney problems or dehydration risk
- Severe gastrointestinal disease
- Diabetic eye disease
- Pregnancy, breastfeeding or plans to become pregnant
- Other prescriptions that may affect blood sugar
Seek urgent medical care for severe or persistent abdominal pain, trouble breathing, swelling of the face or throat, fainting, severe dehydration or another sudden and concerning reaction.
Can You Take Mounjaro and Wegovy Together?
No. Mounjaro should not be used with another incretin treatment such as a GLP-1 receptor agonist. Wegovy should not be used with another semaglutide-containing product or another GLP-1 receptor agonist.
Do not start, stop, overlap or combine prescription treatments without direction from a licensed healthcare provider.
Can You Switch Between Mounjaro and Wegovy?
A provider may consider a change in treatment, but there is no universal switch that applies to everyone. The products have different indications, clinical criteria and treatment instructions.
Before recommending a change, a provider may review:
- The patient’s diagnosis and treatment goal
- Current blood sugar control
- Side effects and previous treatment experience
- Other prescriptions and health conditions
- Cardiovascular, kidney, eye, thyroid, pancreas or gallbladder history
- Insurance coverage and product availability
Do not use leftover medication or follow another person’s treatment plan.
Cost and Insurance Coverage in Canada
There is no single price that applies to every patient. Out-of-pocket cost can vary based on the product prescribed, pharmacy pricing, dispensing fees, province, insurance plan and eligibility for reimbursement.
Insurance plans may require documentation, prior authorization or a diagnosis that matches their coverage rules. Patients should confirm their specific benefits directly with their insurer before assuming either product is covered.
Which One Is More Appropriate?
There is no single answer for everyone. The more appropriate option, if any, depends first on the approved indication and then on the patient’s health history and individual risks.
A licensed healthcare provider may consider age, diagnosis, other prescriptions, cardiovascular or kidney history, eye health, previous reactions, pregnancy plans, insurance coverage and the need for follow-up.
The safest question is not which product receives the strongest claim online. It is which treatment matches the patient’s diagnosis and can be used with an acceptable risk profile.
Questions to Ask a Healthcare Provider
- Which Canadian-approved indication applies to my health situation?
- How do my current prescriptions affect the decision?
- Does my cardiovascular, kidney, eye, thyroid, pancreas or gallbladder history affect eligibility?
- What side effects should I watch for?
- What follow-up or testing may be needed?
- What does my insurance plan cover for my diagnosis?
- What should I do if the prescribed product is unavailable?
Frequently Asked Questions
What is the main difference between Mounjaro and Wegovy?
Mounjaro contains tirzepatide, while Wegovy contains semaglutide. Their Canadian indications also differ: Mounjaro’s current label centres on type 2 diabetes, while Wegovy’s includes chronic weight management and other specific indications.
Are Mounjaro and Wegovy the same medication?
No. They contain different active ingredients and have different Canadian product monographs.
Is Mounjaro approved for chronic weight management in Canada?
The current Canadian Mounjaro product monograph does not list a chronic weight-management indication. Tirzepatide is also found in Zepbound, which is a separate brand with its own Canadian label.
Is Wegovy approved for chronic weight management in Canada?
Yes. The current Canadian product monograph includes chronic weight management for eligible adults and certain adolescents aged 12 to under 18.
Can Mounjaro and Wegovy be used together?
No. Their product monographs advise against combining them or using them with another GLP-1 receptor agonist.
Can someone switch from Mounjaro to Wegovy?
A licensed healthcare provider may consider a change after reviewing the diagnosis, current treatment, health history, side effects and other prescriptions. Patients should not switch or overlap them on their own.
What side effects do they share?
Both may cause gastrointestinal effects such as nausea, diarrhea, vomiting, constipation or abdominal discomfort. They also have product-specific warnings that a provider should review.
Does insurance cover Mounjaro or Wegovy in Canada?
Coverage varies by plan, province, diagnosis and eligibility rules. Patients should confirm coverage directly with their insurer.
Did a clinical trial directly compare Mounjaro with Wegovy?
SURMOUNT-5 compared tirzepatide with semaglutide in adults with obesity without type 2 diabetes. It did not directly compare the Canadian Mounjaro diabetes label with the Canadian Wegovy label.
Key Takeaways
- Mounjaro and Wegovy are different prescription medications.
- Mounjaro contains tirzepatide; Wegovy contains semaglutide.
- Their current Canadian-approved uses and age criteria differ.
- Mounjaro’s current label centres on type 2 diabetes.
- Wegovy’s current label includes chronic weight management and other specific indications.
- They should not be used together.
- A licensed healthcare provider must determine whether either treatment is appropriate.
Related Comparison Guides
Sources Reviewed
You Might Also Like
Learn more about our treatments
